Navigation Links
Drug may treat cystic fibrosis, other diseases caused by 'nonsense mutations,' UAB researcher says

BIRMINGHAM, Ala. Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.

Bedwell is a renowned researcher on the select group of genetic alterations called nonsense mutations DNA alterations that can lead to nonfunctional or missing proteins. He presented recent findings on an experimental drug that may help to treat some cystic fibrosis patients during the Experimental Biology 2010 conference in Anaheim, Calif., April 26. This drug ataluren (formerly called PTC124) also holds promise in treating more than 2,400 different genetic disorders caused by nonsense mutations.

"When you treat a genetic disease, the bottom line is how much of the missing protein do you need to restore to have a therapeutic benefit," Bedwell says. "It comes down to the threshold of protein rescue. For some diseases, it might be 1 percent of protein you need restored, and for other diseases you may need 50 percent of protein restored."

In Bedwell's most well-known study, ataluren restored up to 29 percent of normal protein function in mice with cystic fibrosis. Another researcher not affiliated with UAB has reported ataluren restored up to 25 percent of the missing or abnormal protein function in mice with Duchenne muscular dystrophy.

An estimated one-third of gene defects responsible for human disease are thought to come from nonsense mutations. In the case of cystic fibrosis, the absence of a certain protein leads to an imbalance of salt and water in the linings of the lungs and other membranes. The UAB study showed that ataluren allowed the protein to be made in mouse cells where it was previously absent, and it helped the body's regulatory system to restore salt and water balance in the membrane.

Bedwell says the true promise of drugs that suppress nonsense mutations is their selectiveness, meaning the drugs work well in fixing disease-causing mutations while generally sparing healthy genes.

Ataluren is now being tested in humans for its effectiveness in treating Duchenne/Becker muscular dystrophy, cystic fibrosis, hemophilia A, hemophilia B and other conditions. The agent works in an oral form.


Contact: Troy Goodman
University of Alabama at Birmingham

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Gamma globulin effective in treating eye infections caused by adenoviruses
5. Presence of gene mutation helps guide thyroid cancer treatment
6. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
7. New genetic research into nicotine addiction shows promise for personalized treatment
8. Doctors learn to control their own brains pain responses to better treat patients
9. Interleukin-8, key marker for colorectal cancer treatment
10. New class of drug offers hope to treatment-resistant AIDS patients
11. Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
Post Your Comments:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module to ... of SICM to an AFM. , Park SICM benefits virtually all materials characterization ...
(Date:12/1/2015)... , December 1, 2015 Dr. Harry Lander , President ... serving as Chief Science Officer and recruits five ... Harry Lander , President of Regen, expands his role to ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced ... new closed system for isolating adipose-derived stem cells. The announcement starts a new phase ... tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess adipose ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle ... cale - up through cost ... , where licensees based anywhere in the world will have the right to ... Africa , where licensees based anywhere in the world will have the ...
Breaking Biology Technology: